BioMedNewsBreaks

WednesdayOct 11, 2023 1:34 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including…

Continue Reading

TuesdayOct 10, 2023 2:33 pm

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Welcomes COO Jarrett Boon to Its Board of Directors

Safety Shot (NASDAQ: SHOT) today announced that Jarrett Boon, who has served as the company’s chief operating officer since August 2023, has been appointed to Safety Shot’s board of directors. Boon is leading the launch and growth of the company’s Safety Shot functional drink business this quarter. Boon was the co-founder and CEO of GBB Drink Lab, which developed Safety Shot, the first patented beverage that helps people feel better faster by reducing blood alcohol content and boosting clarity. “In the past few months since I’ve joined the company, our outstanding team has teed up the Safety Shot drink for…

Continue Reading

TuesdayOct 10, 2023 2:29 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Strategic Board Appointments of Two Finance Industry Experts

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, today announced the appointment of Leni Boeren and Ruud Hendriks as independent directors. Both Boeren and Hendriks bring extensive, high-level experience in finance and business. Boeren has a 40-year career in the financial sector, commencing with banking roles at Paribas and Rabobank before holding several director-level positions at Amsterdam exchanges and then Euronext. Hendriks brings more than 35 years of experience in the asset management industry, having held senior roles at some of the most established financial institutions.…

Continue Reading

TuesdayOct 10, 2023 2:22 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) to Serve as Gold Sponsor of Synchrony Symposia 2023

PaxMedica (NASDAQ: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions, today announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023. The globally recognized event serves as a catalyst for translational research in autism and related neurodevelopmental disorders and brings together leading scientists, clinicians, biotech and pharmaceutical companies, venture partners, and community stakeholders to foster scientific advancements that can enhance the well-being and quality of life for individuals affected by ASD. “We are honored to support The BRAIN…

Continue Reading

TuesdayOct 10, 2023 2:11 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview of recent developments, which provide hope to those affected by neurodegenerative conditions. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “Clene spends every waking moment working on amyotrophic lateral sclerosis (‘ALS’), a devastating neurodegenerative condition,” said Clene president…

Continue Reading

TuesdayOct 10, 2023 1:54 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN), UACI Collaborate to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced its entry into development collaboration with the University of Arizona Center for Innovation (“UACI”) to propel ABBIE, a non-viral gene-editing kit technology. UACI is a leading science and tech startup incubator that is directly connected to the University of Arizona, which is renowned for its contributions to the scientific community, ranking among the nation’s top 50 public universities by U.S. News & World Report. “We are delighted to assist SOHM and the development of ABBIE technology,” said UACI Executive…

Continue Reading

MondayOct 09, 2023 1:16 pm

BioMedNewsBreaks – IBN, BioMedWire to Provide Dedicated Media Coverage for Upcoming BioPharma Nexus Events

InvestorBrandNetwork (“IBN”), a dynamic communications organization, today announced its collaboration with BioPharma Nexus as an official media partner for its events this month. In addition, BioMedWire, a specialized communications platform dedicated to the life sciences sector and a key part of IBN’s Dynamic Brand Portfolio (“DBP”), will serve as an official media partner. For each of the events, IBN and BioMedWire will leverage advanced communications tools to provide dedicated coverage, including syndicated article dissemination throughout IBN’s extensive network of 5,000+ strategic partners, and offer updates on each event via IBN’s influential social media accounts. “It is a pleasure to work…

Continue Reading

MondayOct 09, 2023 12:34 pm

BioMedNewsBreaks – ROTH MKM’s Upcoming Conference to Feature Public Healthcare Companies Across Multiple Sub-Sectors

ROTH MKM, a full-service investment bank focused on serving growth companies and their investors, today announced plans to host its 2023 Healthcare Opportunities Conference in New York City on Oct. 12, 2023. The event will provide pre-qualified institutional investors and healthcare industry professionals the opportunity to interact closely with C-level executives of approximately 25 public companies selected by ROTH’s research analysts. With a multiple sub-sector focus, the conference will feature participating companies operating in biotechnology, pharmaceuticals, medical technologies and oncology therapeutics. “Meaningful conversations between companies and a wide spectrum of investors will be the main focus of our Healthcare Opportunities…

Continue Reading

FridayOct 06, 2023 11:39 am

BioMedNewsBreaks – Safety Shot Holdings Inc. (NASDAQ: SHOT) Announces Ring Sponsorship of Jorge Masvidal’s Gamebred Bareknuckle MMA

Safety Shot (NASDAQ: SHOT) today announced its entry into an agreement with mixed martial arts (“MMA”) superstar Jorge Masvidal’s Gamebred Bareknuckle MMA, the world’s first bareknuckle MMA promotion. Over the next year, Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, will be the ring sponsor for 12 Gamebred Bareknuckle matches. “Jorge is a superstar in the MMA world with a huge following and his Gamebred Bareknuckle fight promotion has garnered a fast growing following with millions of people viewing matches online and live audiences cheering at…

Continue Reading

ThursdayOct 05, 2023 12:06 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer’s Disease Score (“CADS”) also demonstrated positive results. The report also noted that other doses demonstrated numerical…

Continue Reading